Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 3
2020 4
2021 2
2022 4
2023 1
2024 1
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 30043658

19 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA. Selmaj KW, et al. Mult Scler. 2025 Nov;31(13):1557-1571. doi: 10.1177/13524585251382796. Epub 2025 Nov 5. Mult Scler. 2025. PMID: 41190505 Free PMC article. Clinical Trial.
Case Report: Asymptomatic macular edema in ozanimod.
Mauceri VA, Torresin T, Basili E, Gaggiola M, Rinaldi F, Baroni F, Gallo P, Perini P, Pilotto E, Puthenparampil M. Mauceri VA, et al. Front Ophthalmol (Lausanne). 2025 Oct 7;5:1632065. doi: 10.3389/fopht.2025.1632065. eCollection 2025. Front Ophthalmol (Lausanne). 2025. PMID: 41127406 Free PMC article.
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.
Galota F, Marcheselli S, De Biasi S, Gibellini L, Vitetta F, Fiore A, Smolik K, De Napoli G, Cardi M, Cossarizza A, Ferraro D. Galota F, et al. Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606. Cells. 2025. PMID: 40277931 Free PMC article. Review.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA. Cree BA, et al. Mult Scler. 2022 Oct;28(12):1944-1962. doi: 10.1177/13524585221102584. Epub 2022 Jun 28. Mult Scler. 2022. PMID: 35765217 Free PMC article. Clinical Trial.
19 results